Perfect Crypto Buying Opportunity for 50 Cents

When cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious Bank

Go here to get full details on this crypto now.

Gary Pruden Biography and Net Worth

Director of Lantheus

Gary J. Pruden is a Director, the Chairperson of the Talent and Compensation Committee and a member of the Audit Committee, serving on the Board of Directors since February 2018. Most recently, Mr. Pruden held a number of senior commercial leadership positions across both the medical device and pharmaceutical sectors of Johnson & Johnson (“J&J”) from 1985 until 2017. In April 2016, Mr. Pruden was appointed as a member of the Executive Committee of J&J, where his official title was Executive Vice President, Worldwide Chairman, Medical Devices. Prior to that, he held roles of increasing responsibility within J&J, serving as Worldwide Chairman in the Medical Devices division from 2015 to 2016, as Worldwide Chairman of Global Surgery Group from 2012 to 2015, as Company Group Chairman of Ethicon, Inc. from 2009 to 2012, as Worldwide President of Ethicon, Inc., a J&J subsidiary, from 2006 to 2009, and as President of the J&J subsidiary, Janssen-Ortho Inc. in Canada, from 2004 to 2006. Mr. Pruden has also served in several capacities, including Chairman of Technology & Regulatory Committee and Executive Committee Member with the Advanced Medical Technology Association, a medical device trade association. Mr. Pruden currently serves on the Board of Directors of Motus GI Holdings, Inc., Ossio, Inc. and Olympus Corporation. Mr. Pruden received his Bachelor of Science in finance at Rider University, where he later served on the Board of Trustees from 2011 until 2015.

What is Gary J. Pruden's net worth?: The estimated net worth of Gary J. Pruden is at least $1.22 million as of July 10th, 2024. Mr. Pruden owns 11,978 shares of Lantheus stock worth more than $1,221,516 as of September 7th. This net worth evaluation does not reflect any other assets that Mr. Pruden may own. Learn More about Gary J. Pruden's net worth.
How do I contact Gary J. Pruden?: The corporate mailing address for Mr. Pruden and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at [email protected]. Learn More on Gary J. Pruden's contact information.
Has Gary J. Pruden been buying or selling shares of Lantheus?: During the past quarter, Gary J. Pruden has sold $1,190,851.20 in Lantheus stock. Most recently, Gary J. Pruden sold 12,530 shares of the business's stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a transaction totalling $1,190,851.20. Following the completion of the sale, the director now directly owns 11,978 shares of the company's stock, valued at $1,138,389.12. Learn More on Gary J. Pruden's trading history.
Who are Lantheus' active insiders?: Lantheus' insider roster includes Minnie Baylor-Henry (Director), Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Brian Markison (Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Gary Pruden (Director), Andrea Sabens (CAO), and Carol Walker (SVP). Learn More on Lantheus' active insiders.
Are insiders buying or selling shares of Lantheus?: During the last year, Lantheus insiders bought shares 1 times. They purchased a total of 60,431,039 shares worth more than $57,409,487.05. During the last year, insiders at the medical equipment provider sold shares 17 times. They sold a total of 184,133 shares worth more than $13,710,751.80. The most recent insider tranaction occured on August, 12th when Director Gerard Ber sold 15,500 shares worth more than $1,495,440.00. Insiders at Lantheus own 1.5% of the company. Learn More about insider trades at Lantheus.
Information on this page was last updated on 8/12/2024.

Gary J. Pruden Insider Trading History at Lantheus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/10/2024	Sell	12,530	$95.04	$1,190,851.20	11,978

Gary J. Pruden Buying and Selling Activity at Lantheus

Lantheus Company Overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Today's Range

Now: $101.98

$101.81

$108.18

50 Day Range

MA: $102.61

$77.70

$123.62

2 Week Range

Now: $101.98

$50.20

$126.89

Volume

561,405 shs

Average Volume

1,036,350 shs

Market Capitalization

$7.07 billion

P/E Ratio

15.57

Dividend Yield

N/A

Beta

0.51

Why billionaires are wiring money to abandoned towns

From Porter & Company | Ad

A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution.

Click here for my exclusive video